32.65
-0.46%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sofiva Genomics Co
Its shares trade on Taipei Exchange under the ticker 6615.TWO. It has been listed since 5 January 2017. In the fiscal year to 31 December 2025, it reported revenue of TWD 385.7m and a net loss of TWD 9.4m. At that date it held total assets of TWD 724.3m and shareholders' equity of TWD 628.1m.
Sofiva Genomics Co., Ltd. engages in the provision of pre-pregnancy, prenatal, and newborn genetic testing and medical testing services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2017-01-05. The firm's DNA testing services mainly contain reproductive medicine testing, pregnant women testing, newborn testing, rare disease genetic testing, personalized genetic testing, cancer genetic testing, and genetic counseling services. Reproductive Medicine testing is pre-implantation genetic diagnosis for embryos. Pregnant women testing services predict the occurrence of preeclampsia and provide prenatal diagnosis. Neonatal testing services provide neonatal hearing loss genetic test, respiratory distress syndrome test, congenital cytomegalovirus infection test service. Personalized genetic testing services includes human papilloma virus screening, paternity testing, telomere testing, chronic disease and cardiovascular disease and other genetic research. Cancer genetic testing services is applied to cancer patients.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 5 Jan 2017
- Website
- sofivagenomics.com.tw/zh-tw ↗
Leadership
Pay as last reported
- Mr. Yi-Ning SuChairman of the Board, since 2012
- Mr. Chia Cheng HungGeneral Manager
- Ms. Huihua LuoDeputy General Manager
- Fujian ZhangHead of Finance
- Ms. Junhui ChenDirector
- Mr. Tingyu ChenDirector
- Ms. Lijuan LiDirector
- Mr. Chien-Nan LeeIndependent Director
- Ms. Joanne PanIndependent Director
- Mr. Fanquan ShiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Provides pre-pregnancy, prenatal, and newborn genetic testing services
- Offers a range of genetic testing including reproductive medicine and cancer genetic testing
- Headquartered in Taipei City, Taiwan
Weaknesses
- No specific weaknesses mentioned in the provided information
- Limited to genetic testing services without additional financial data
- No details on market share or competitive advantages
Opportunities
- Expansion into personalized genetic testing and cancer genetic testing markets
- Growth potential in reproductive medicine testing services
- Increasing demand for genetic counseling services
Threats
- Competition from other genetic testing providers
- Regulatory challenges in the health care sector
- Dependence on specific market segments like prenatal testing
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.